GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...

The company ecently announced that the FDA granted accelerated approval for Livdelzi in combination with ursodeoxycholic acidfor the treatment of primary biliary cholangitis, the analyst tells ...

The study enrolled 238 people with primary biliary cholangitis (PBC) and cholestatic pruritus, a medical term for relentless ...

The London-based pharmaceutical company said that in cholestatic pruritus, also known as relentless itch, in primary biliary cholangitis, an autoimmune disease known as PBC, linerixibat showed a ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...

in adults with cholestatic pruritus associated with primary biliary cholangitis, a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat resulting in an improvement in itch ...